Cis-diamminedichloroplatinum II in advanced urothelial cancer

M. S. Soloway

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Thirteen patients with advanced urothelial cancer received a minimum of 2 courses of cis-diamminedichloroplatinum II. Of these patients 6 (46%) achieved a partial response with an average duration of more than 6 months. One patient has received cis-diamminedichloroplatinum for more than 1 year and has no clinical evidence of tumour (complete response in lung metastasis plus excision of local recurrence). The routine administration of intravenous fluids and mannitol immediately before cis-diamminedichloroplatinum prevented the nephrotoxicity associated with this drug. An outpatient setting was well tolerated in most instances. This report confirms the activity of cis-diamminedichloroplatinum in urothelial cancer and suggests its use as an adjuvant to operation and/or radiotherapy in selected cases.

Original languageEnglish
Pages (from-to)716-719
Number of pages4
JournalJournal of Urology
Volume120
Issue number6
StatePublished - Dec 1 1978
Externally publishedYes

Fingerprint

Cisplatin
Neoplasms
Mannitol
Intravenous Administration
Outpatients
Radiotherapy
Neoplasm Metastasis
Recurrence
Lung
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Urology

Cite this

Cis-diamminedichloroplatinum II in advanced urothelial cancer. / Soloway, M. S.

In: Journal of Urology, Vol. 120, No. 6, 01.12.1978, p. 716-719.

Research output: Contribution to journalArticle

Soloway, MS 1978, 'Cis-diamminedichloroplatinum II in advanced urothelial cancer', Journal of Urology, vol. 120, no. 6, pp. 716-719.
Soloway, M. S. / Cis-diamminedichloroplatinum II in advanced urothelial cancer. In: Journal of Urology. 1978 ; Vol. 120, No. 6. pp. 716-719.
@article{f380d94638f443f09f647bf05a26b70a,
title = "Cis-diamminedichloroplatinum II in advanced urothelial cancer",
abstract = "Thirteen patients with advanced urothelial cancer received a minimum of 2 courses of cis-diamminedichloroplatinum II. Of these patients 6 (46{\%}) achieved a partial response with an average duration of more than 6 months. One patient has received cis-diamminedichloroplatinum for more than 1 year and has no clinical evidence of tumour (complete response in lung metastasis plus excision of local recurrence). The routine administration of intravenous fluids and mannitol immediately before cis-diamminedichloroplatinum prevented the nephrotoxicity associated with this drug. An outpatient setting was well tolerated in most instances. This report confirms the activity of cis-diamminedichloroplatinum in urothelial cancer and suggests its use as an adjuvant to operation and/or radiotherapy in selected cases.",
author = "Soloway, {M. S.}",
year = "1978",
month = "12",
day = "1",
language = "English",
volume = "120",
pages = "716--719",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Cis-diamminedichloroplatinum II in advanced urothelial cancer

AU - Soloway, M. S.

PY - 1978/12/1

Y1 - 1978/12/1

N2 - Thirteen patients with advanced urothelial cancer received a minimum of 2 courses of cis-diamminedichloroplatinum II. Of these patients 6 (46%) achieved a partial response with an average duration of more than 6 months. One patient has received cis-diamminedichloroplatinum for more than 1 year and has no clinical evidence of tumour (complete response in lung metastasis plus excision of local recurrence). The routine administration of intravenous fluids and mannitol immediately before cis-diamminedichloroplatinum prevented the nephrotoxicity associated with this drug. An outpatient setting was well tolerated in most instances. This report confirms the activity of cis-diamminedichloroplatinum in urothelial cancer and suggests its use as an adjuvant to operation and/or radiotherapy in selected cases.

AB - Thirteen patients with advanced urothelial cancer received a minimum of 2 courses of cis-diamminedichloroplatinum II. Of these patients 6 (46%) achieved a partial response with an average duration of more than 6 months. One patient has received cis-diamminedichloroplatinum for more than 1 year and has no clinical evidence of tumour (complete response in lung metastasis plus excision of local recurrence). The routine administration of intravenous fluids and mannitol immediately before cis-diamminedichloroplatinum prevented the nephrotoxicity associated with this drug. An outpatient setting was well tolerated in most instances. This report confirms the activity of cis-diamminedichloroplatinum in urothelial cancer and suggests its use as an adjuvant to operation and/or radiotherapy in selected cases.

UR - http://www.scopus.com/inward/record.url?scp=0018237343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018237343&partnerID=8YFLogxK

M3 - Article

C2 - 731813

AN - SCOPUS:0018237343

VL - 120

SP - 716

EP - 719

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -